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Abstract
Lipid A is a highly conserved component of lipopolysaccharide (LPS), itself a major compo-
nent of the outer membrane of Gram-negative bacteria. Lipid A is essential to cells and
elicits a strong immune response from humans and other animals. We developed a quanti-
tative model of the nine enzyme-catalyzed steps of Escherichia coli lipid A biosynthesis,
drawing parameters from the experimental literature. This model accounts for biosynthesis
regulation, which occurs through regulated degradation of the LpxC andWaaA (also called
KdtA) enzymes. The LpxC degradation signal appears to arise from the lipid A disaccharide
concentration, which we deduced from prior results, model results, and new LpxK overex-
pression results. The model agrees reasonably well with many experimental findings, in-
cluding the lipid A production rate, the behaviors of mutants with defective LpxA enzymes,
correlations between LpxC half-lives and cell generation times, and the effects of LpxK
overexpression on LpxC concentrations. Its predictions also differ from some experimental
results, which suggest modifications to the current understanding of the lipid A pathway,
such as the possibility that LpxD can replace LpxA and that there may be metabolic
channeling between LpxH and LpxB. The model shows that WaaA regulation may serve to
regulate the lipid A production rate when the 3-deoxy-D-manno-oct-2-ulosonic acid (KDO)
concentration is low and/or to control the number of KDO residues that get attached to lipid
A. Computation of flux control coefficients showed that LpxC is the rate-limiting enzyme if
pathway regulation is ignored, but that LpxK is the rate-limiting enzyme if pathway regula-
tion is present, as it is in real cells. Control also shifts to other enzymes if the pathway sub-
strate concentrations are not in excess. Based on these results, we suggest that LpxK may
be a much better drug target than LpxC, which has been pursued most often.
Introduction
Lipopolysaccharide (LPS) is a glycolipid that forms the major component of the outer leaflet of
the outer membrane of most Gram-negative bacteria. It occurs with roughly 1 million copies in
Escherichia coli cells, covering about 75% of the cell surface area [1],[2],[3]. LPS helps stabilize
these membranes, protects them from chemical attack, and promotes cell adhesion to various
PLOSONE | DOI:10.1371/journal.pone.0121216 April 28, 2015 1 / 28
OPEN ACCESS
Citation: Emiola A, George J, Andrews SS (2015) A
Complete Pathway Model for Lipid A Biosynthesis in
Escherichia coli. PLoS ONE 10(4): e0121216.
doi:10.1371/journal.pone.0121216
Academic Editor: Hendrik W. van Veen, University
of Cambridge, UNITED KINGDOM
Received: March 1, 2014
Accepted: February 12, 2015
Published: April 28, 2015
Copyright: © 2015 Emiola et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Funding: SSA was funded in part by National
Institute of General Medical Science grant R01
GM08666615, awarded to Roger Brent and Richard
Yu. There were no addition internal/external funding
sources. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
surfaces [4]. It elicits a strong immune response in humans and other animals (and is a main
contributor to Gram-negative septic shock), getting detected at picomolar levels by the innate
immune system’s TLR4 protein [5]. These attributes have made the study of LPS important to
the fields of immunology, bacteriology, and drug discovery [1],[2],[5],[6],[7],[8].
LPS comprises three components: lipid A, core oligosaccharide, and O-antigen [1],[5]. The
lipid A, or endotoxin component (Fig 1) includes six hydrophobic acyl chains that reside in the
outer leaflet of the bacterial outer membrane. These are connected together by a glucosamine
and phosphate head group. In most Gram-negative bacteria, including E. coli, this head group
connects to a pair of KDO sugar residues (3-deoxy-D-manno-oct-2-ulosonic acid) [1]. These
KDO residues connect to several additional sugar residues, and sometimes also to phosphate,
pyrophosphorylethanolamine, or phosphorylcholine residues, which together form the core ol-
igosaccharide [5]. This core then connects to the O-antigen, which is a long polysaccharide
that varies widely between different bacterial species and different strains within each species
[5]. Of these three components, the lipid A moiety is of particular interest because it is the only
component that is essential for cell viability and is highly conserved [5]. These also make its
biosynthetic pathway an attractive target for new antibiotics [5],[9],[10],[11].
Fig 1. Structure of KDO2-lipid A. The top two sugars are KDO groups, which are part of the core
oligosaccharide, while the remainder of the structure represents lipid A.
doi:10.1371/journal.pone.0121216.g001
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The lipid A biosynthesis pathway architecture, shown in Fig 2 and described in more detail
below, has been investigated thoroughly through several decades of careful experimentation
[1],[2],[5],[7],[8]. However, it has received remarkably little quantitative analysis, which is es-
sential for testing the internal consistency of models and for investigating pathway regulation
mechanisms. In one modeling study, Kenanov et al. [12] investigated the elementary flux
modes (unbranched paths through the metabolic chemical reaction network, not including
regulatory interactions) for the biosynthesis of all E. coli lipids. They found close agreement be-
tween the predicted and experimental viability of knock-out mutants. This supported the lipid
biosynthesis pathway architecture that they used, which is also the one that is commonly ac-
cepted and that which we assume in this work. In other modeling work, we recently simulated
the chemical kinetics of the first two steps of lipid A biosynthesis [13]. We found that the sec-
ond enzyme (LpxC) has sufficient catalytic activity to overcome the first enzyme’s unfavour-
able equilibrium constant. We are not aware of any other computational models of lipid A
biosynthesis.
Here, we build on the prior experimental and modeling work to present a quantitative
model of the central steps of lipid A biosynthesis. This model is specific to E. coli because E. coli
has been the subject of most lipid A research. However, the lipid A biosynthesis pathway is well
conserved across Gram-negative bacteria [5], so our model may be applicable to other Gram-
negative bacteria as well. We used published parameters where possible and estimated others
as required. Our model can reproduce the observed lipid A production rate and agrees reason-
ably well with results from several lipid A biosynthesis experiments. These include data that
correlated LpxC half lives and cell generation times [14], and our own experiments on LpxK
overexpression. Our model also disagrees with several experimental results. These disagree-
ments highlight potentially interesting biological behaviour such as metabolic channeling and
additional sources of pathway regulation.
Methods
Simulations
Simulations were performed with non-spatial deterministic methods using the COPASI soft-
ware [15]. This level of detail was determined to be adequate because preliminary simulations
using spatial stochastic simulations (with Smoldyn [16]) and non-spatial stochastic simulations
(with StochKit [17]) yielded essentially identical results. The COPASI files are available as sup-
plementary information and will be submitted to the BioModels database.
Experimental procedures
Bacterial strain and growth conditions. An E. coli K-12 strain AG1 (recA1, endA1,
gyrA96, thi-1, hsdR17(rK
- mK
+), supE44, relA1) containing a plasmid (pCA24N) [18] bearing E.
coli LpxK-GFP gene fusion (to the C-terminus) was obtained from the National BioResource
Project (NIG) Japan. Cells were grown at 30°C in LB media (10g tryptone, 5g yeast extract, 5g
NaCl per liter) containing 20 μg/ml of chloramphenicol and when required, protein expression
was induced using IPTG (Sigma, UK).
Preparation of cell extracts. Cell extracts were prepared as described previously [19],[20].
Briefly, an overnight culture was inoculated into fresh LB containing different concentrations
of IPTG at an OD600 of 0.05 and grown to mid log phase (OD600 = 0.5). The respective cultures
were normalized to the same OD600 of 0.5. 3 ml of normalized culture was centrifuged at
13,000 rpm for 1 min and the cell pellets re-suspended in 100 μl of 2x Laemmli sample buffer
(Sigma, UK). The samples were heated for 10 min prior to centrifugation for 5 min. The super-
natants were collected for Western blot analysis.
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Fig 2. Model of the E. coliKDO2-lipid A biosynthesis pathway. Enzymes and metabolites are shown with
three text styles: upright bold indicates that these concentrations are fixed, upright plain indicates that these
concentrations vary, and italics indicates that these species are not included in the model explicitly. Black
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Western blot. 20 μl of each sample were loaded onto a 10% SDS-polyacrylamide gel. Fol-
lowing electrophoresis, proteins were transferred to a PVDF membrane using the Bio-Rad
Trans-Blot Turbo system. An LpxC antiserum generated in rabbit (a generous gift from Prof.
Franz Narberhaus) and a secondary anti-rabbit peroxidase-linked antibody (Sigma, UK) were
used for immunodetection at dilutions of 1:20000 and 1:10000 respectively. Blots were devel-
oped using the ECL chemiluminiscent reagents (Bio-Rad) and the signals detected using the
ChemiDoc MP system (Bio-Rad).
Model architecture
Lipid A biosynthesis pathway. E. coli lipid A biosynthesis proceeds through nine enzyme-
catalyzed steps, which are sometimes referred to as the Raetz pathway [2],[7] (Fig 2). All of
these enzymes are constitutively expressed [5]. The pathway has been reviewed several times
recently [1],[2],[5] [7],[8], so we only provide a brief summary here, while focusing on the fea-
tures that are particularly salient to our model.
Lipid A biosynthesis begins with the UDP-N-acetylglucosamine (UDP-GlcNAc) and β-
hydroxymyristoyl-ACP substrates. Both substrates are consumed in other metabolic pathways
as well [21]: UDP-GlcNAc is a substrate in peptidoglycan synthesis [22],[23] and β-hydroxy-
myristoyl-ACP is a precursor for phospholipid metabolism [24],[25],[26].
The first three steps of the lipid A pathway occur in the cytoplasm. First, LpxA (EC
2.3.1.129) acylates UDP-GlcNAc with β-hydroxymyristoyl-ACP. This reaction has an unfa-
vourable equilibrium constant of 0.01 in vitro [27], suggesting that the reaction products are
not committed to proceed on through the lipid A pathway but may instead revert back into the
pathway substrates. The product is then deacetylated by LpxC (EC 3.5.1.108) in an essentially
irreversible reaction, making this the first committed pathway step [19],[28],[29],[30]. For this
and other reasons, LpxC is likely to be a primary biosynthesis control point [27] (and is a
prime drug target), as discussed below. The third pathway enzyme, LpxD (EC 2.3.1.191), incor-
porates a second hydroxymyristate moiety onto the lipid A precursor [31],[32]. LpxD is similar
to LpxA in that they are acyltransferases, and consume the same β-hydroxymyristoyl-ACP sub-
strate [32]. Both LpxD reaction products inhibit the LpxD reaction, acting as either competitive
or non-competitive inhibitors against each substrate [32]. We simplified this by only including
non-competitive inhibition by UDP-2,3-bis(β-hydroxymyristoyl)-D-glucosamine. Ignoring in-
hibition by ACP had minimal effect on our results because we fixed its concentration.
The fourth and fifth lipid A biosynthesis steps are catalyzed by the peripheral membrane
proteins LpxH (EC 3.6.1.54) [33] and LpxB (EC 2.4.1.182) [34]. LpxH cleaves most of the UDP
moiety to leave just a single phosphate on the remaining lipid portion, which is called lipid X.
Feedback regulation has not been proposed before for LpxH but proved necessary for our
model to achieve steady-state behaviour, as described below. Then, LpxB combines lipid X
with the preceding lipid metabolite, UDP-2,3-bis(β-hydroxymyristoyl)-D-glucosamine, to
form lipid A disaccharide [34].
The remaining four steps of lipid A biosynthesis are catalyzed by integral membrane en-
zymes. LpxK (EC 2.7.1.130) is a kinase that phosphorylates lipid A disaccharide to produce
lipid IVA [35],[36]. Remarkably, Lipid IVA has been reported to be an endotoxin agonist in
mouse cells and an endotoxin antagonist in human cells [37]. Next, WaaA (previously called
arrows with barbed heads represent chemical reactions in which reactants are converted to products. Red
arrows with closed heads represent enzymatic influences on chemical reaction rates, and red arrows with T-
bar heads represent inhibitory influences. Variables represent model parameters. Numbers next to black
arrows for bi-substrate reactions show which substrate is designated number 1 and number 2.
doi:10.1371/journal.pone.0121216.g002
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KdtA, EC 2.4.99.12/13) sequentially transfers two KDO sugar residues to lipid IVA to produce
KDO2-lipid IVA [38],[39],[40]. WaaA has low substrate specificity, with the result that KDO2-
lipid A can act as a competitive inhibitor for this reaction [40], or as another possible WaaA
substrate [39],[40]; in the latter case, the reaction produces “alternate lipid A”, which we define
as having more than 2 KDO sugar residues. In addition, the WaaA reaction has been shown to
be reversible, based on the finding that in vitro combinations of the reaction products (enzyme,
cytidine 5'-monophosphate (CMP), and KDO2-lipid IVA) led to detectible concentrations of
the KDO-lipid IVA intermediate [40]. However, the authors only observed trace quantities of
lipid IVA even after prolonged incubations, thus, the forward reaction is likely to be strongly
thermodynamically favourable, and in which case, the in vivo back-reaction rate is probably
negligible. For this reason, our model treats WaaA catalysis as being irreversible. Finally, the
“late acyltransferases,” LpxL (EC 2.3.1.-) [41] and LpxM (EC 2.3.1.-) [42],[43], incorporate
lauroyl and myristoyl chains to the KDO2-lipid IVA, thus giving the final KDO2-lipid A prod-
uct six acyl chains. Cells are still viable without LpxM, or without LpxL and with overexpressed
LpxM [44]. In cold-adapted E. coli, the LpxL function is replaced by LpxP (EC 2.3.1.-), which
incorporates a palmitoleate instead of the laurate, presumably as a way of adjusting membrane
fluidity [45].
After synthesis, KDO2-lipid A is joined to core oligosaccharide and then flipped from the
inner leaflet of the inner membrane to the outer leaflet of the inner membrane by MsbA (EC
3.6.3.39), an ABC transporter [2],[46]. Next, several enzymes add the O-antigen to form LPS,
and then transport the LPS on to the outer leaflet of the outer membrane [7].
Lipid A biosynthesis regulation. Lipid A synthesis is regulated, at least in part, through
controlled degradation of LpxC [47],[48],[49] andWaaA [50], both performed by FtsH (EC
3.4.24.—). FtsH is an integral membrane AAA-type metalloprotease that degrades a wide varie-
ty of proteins. These include heat shock transcription factor RpoH (σ32), phage λ proteins CII
and CIII, and many misfolded proteins [51],[52]. FtsH is an essential protein due to its role in
regulating LpxC [47],[53]. Lipid A biosynthesis regulation is less well established than is the
synthetic pathway, so we describe these aspects of our model in more detail.
We assume that FtsH can reversibly convert between an inactive state, an active state for de-
grading LpxC, and a different active state for degrading WaaA (denoted FtsH, FtsHLpxC, and
FtsHWaaA, respectively). This assumption of substrate-specific FtsH activation is supported by
several findings: (i) FtsH degradation of RpoH and λ CII is substrate-specific, accomplished
through separate adapter proteins [52],[54], (ii) neither increased nor decreased FtsH degrada-
tion of LpxC have a significant effect on the intracellular concentration of RpoH [47] or the ac-
tivity of WaaA [19], and (iii) LpxC is degraded more slowly at higher temperatures whereas
WaaA is degraded more rapidly at higher temperatures [14],[50]. Substrate-specific activation
of FtsH for LpxC may occur through YciM acting as an LpxC adapter protein [55].
We assume that the regulatory signal that directs FtsH degradation of LpxC arises from the
concentration of lipid A disaccharide. Again, this is based on several findings. First, strains that
have decreased LpxA, LpxC, or LpxD function, whether through temperature-sensitive mu-
tants or chemical inhibition, exhibit decreased lipid A content and slowed LpxC degradation
[11],[19],[27],[56]. These suggest that the feedback source is downstream of LpxD. Second,
chemically inhibiting CMP-KDO production [57] blocks the lipid A biosynthesis pathway at
the WaaA point. This was found to cause lipid IVA accumulation but did not affect LpxC activ-
ity [19]. This suggests that the feedback source is upstream of lipid IVA. Three metabolites fit
these two criteria, UDP-2,3-bis(β-hydroxymyristoyl)-D-glucosamine, lipid X, and lipid A di-
saccharide. Of these, UDP-2,3-bis(β-hydroxymyristoyl)-D-glucosamine was already regulated
by product inhibition, which makes its concentration a poor indicator of pathway flux and
hence a poor candidate. Preliminary simulations that represented FtsH knock-out mutants,
AModel for Lipid A Biosynthesis in E. coli
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and hence did not include FtsH regulation, exhibited lipid A disaccharide accumulation
(Fig 3). This suggested that the feedback source is lipid A disaccharide. Guided by these argu-
ments, we experimentally investigated the effect of over-expressing LpxK; those results further
supported the lipid A disaccharide choice, as explained below.
Finally, we assume that the regulatory signal for FtsH degradation of WaaA arises from
KDO2-lipid A that is inside the inner membrane. We chose KDO2-lipid A rather than its pre-
cursors because the two enzymes downstream of WaaA, which are LpxL and LpxM, are non-
essential [44], making their substrates unlikely activators. Also, we chose KDO2-lipid A before
it has been transported to the outer membrane, rather than afterwards, because bacterial cells
are known to regulate excess lipid A in their outer membrane by shedding it into the environ-
ment [58].
Other regulatory signals impinge upon the lipid A biosynthesis pathway as well but are out-
side of the scope of this work. In particular, modifications to the FabZ and FabI enzymes, used
for phospholipid synthesis, have been shown to affect the concentration of LpxC and hence af-
fect the rate of lipid A production [20],[24],[47]. By assuming that FabZ and FabI are main-
tained at wild-type conditions, and that there are no feedback processes from the lipid A
pathway that affect the FabZ or FabI regions of the phospholipid pathway, we were able to le-
gitimately ignore these additional regulatory signals in this work.
Model Equations and Parameters
Wemodeled the interactions of individual substrates and enzymes for a single E. coli cell at
steady state. We assumed that the volume of a cell is 6.7×10–16 liters [59] (thus 1 molecule
represents 2.5 nM, 1000 molecules represents 2.5 μM, and 106 molecules represents 2.5 mM).
Unless specified otherwise, we assumed a 30 minute (1800 s) doubling time, which is the
experimental value in rich media [60], [61]. For the most part, we did not account for protein
Fig 3. Lipid A disaccharide accumulation. Bars indicate intracellular counts of lipid X and lipid A
disaccharide at the end of a single cell generation from preliminary model results. The model used the
scheme shown in Fig 2 and parameters listed in Table 1, with the exceptions: the FtsH count was set to zero,
the LpxC andWaaA counts were set to their steady-state levels in the absence of FtsH degradation (1540
and 978, respectively), and all metabolites were started with zero molecules. Although not shown here, the
lipid X count had stabilised at a constant level, while the lipid A disaccharide count was increasing at a
constant rate of 924 molecules/s.
doi:10.1371/journal.pone.0121216.g003
AModel for Lipid A Biosynthesis in E. coli
PLOSONE | DOI:10.1371/journal.pone.0121216 April 28, 2015 7 / 28
synthesis, protein degradation, or cell volume growth during a cell generation. These approxi-
mations are legitimate because metabolic enzyme concentrations for constitutive enzymes like-
ly remain constant over the course of the cell cycle. Table 1 lists our model parameters, along
with the relevant data sources.
Substrate concentrations. We investigated lipid A metabolism with either excess or limit-
ing concentrations of the UDP-GlcNAc, β-hydroxymyristoyl-ACP, and CMP-KDO substrates.
The stoichiometric ratios of these substrates to lipid A are 2:1, 4:1, and 2:1, respectively, due to
consumption of multiple copies and/or lipid dimerization by LpxB. The first two of these sub-
strates are also precursors for other biosynthetic pathways [21], [22], [23], [25], so their rela-
tive concentrations are controlled by factors outside our simulation. We kept their levels
constant at 2 million molecules (5 mM) throughout most simulations, which led to substrate
saturation conditions. Additionally, we fixed the ACP level to 1024 molecules, based on proteo-
mic results [62].
Enzyme abundance. We used LpxA, LpxD, WaaA, MsbA, and FtsH protein copy num-
bers from mass spectrometry proteomic data collected on E. coli cytosolic fractions [62]. Sever-
al of these are integral membrane proteins, so their experimental protein counts are likely to be
lower limits for their true counts in a cell. We used the same proteomic data source for the
copy number of LpxM [62], another integral membrane protein, but then increased the count
20-fold as described below. We calculated LpxC, LpxH, and LpxB protein counts from protein
purification data [13][33][63], along with the assumption that an average E. coli cytoplasm
contains approximately 1.9 million protein molecules [64]. Similarly, we calculated LpxL
Table 1. Abundance and kinetic parameters of lipid A biosynthesis model.
Species Location Abundance(molec./cell) Km or Km1 (mM) Km2(mM) kcat(s-1) Notes and other parameters
UDP-GlcNAc 2,000,000 excess concentration
β-hydroxymyristoyl-
ACP
2,000,000 excess concentration
CMP-KDO 2,000,000 excess concentration
ACP 1024a actual concentration
LpxA cyto. 664a 0.82f 0.0016m 7.17f
0.82 0.0016 717 back reaction
LpxC cyto. 385b 0.00019 g 3.3l ktranslate = 0.148 s
-1 kdegrade = 9.62×10
–5 s-1
LpxD cyto. 453a 0.0025h 0.0032h 23h Ki = 0.0094 mM
h
LpxH p.m. 177c 0.0617c 47 Ki = 0.015 mM
LpxB p.m. 384d 0.287d 0.381d 129
LpxK i.m. 432 0.04i 2.1
WaaA i.m. 153a 0.088j 0.052j 16.7 Ki = 0.0317 mM ktranslate = 0.176 s
-1 kdegrade = 1.8×10
–4 s-1
0.088j 0.052j 1.9 substrate is KDO2-lipid A
LpxL i.m. 928e 0.015k 131k
LpxM i.m. 3720 0.00275 0.6
MsbA i.m. 206a 0.021 166
FtsH i.m. 579a
FtsH*LpxC i.m. - kFtsH = 2.0 mM
-1s-1 kactive = 0.14 mM
-1s-1 kinactive = 0.1 s
-1
FtsH*WaaA i.m. - kFtsH = 6.8 mM
-1s-1 kactive = 32.3 mM
-1s-1 kinactive = 0.1 s
-1
These values are for E. coli cells in rich media. Location abbreviations are: cyto. for cytoplasm, p.m. for peripheral membrane, and i.m. for integral
membrane (locations are not part of the model). Data estimation methods are presented in the main text. Data are from: (a) [62], (b) [13], (c) [33], (d) [63],
(e) [41], (f) [76], (g) [94], (h) [32], (i) Fig 5 in [35], (j) [40], (k) [95], (l) [96], (m) [27]. Parameters that do not have citations are discussed in the main text.
doi:10.1371/journal.pone.0121216.t001
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protein counts from protein purification experiments [41] and the estimate that an E. coli
membrane contains 580,000 proteins [64].
We estimated the LpxK protein count using information about MsbA. These proteins are
co-transcribed [65], implying that their transcripts are synthesized at similar rates. Thus, dif-
ferences in their expression rates depend on the relative stability of their transcripts and on the
translation rates for individual proteins. The MsbA and LpxK transcript half-lives have been
reported as 3.2 min and 3.8 min respectively [66], from which we calculated their mean life-
times as 277 s and 329 s. Given that the average translation rate is 20 amino acids per second
[67], and that they comprise 582 [68] and 328 amino acids respectively [36], it should take
about 29 s and 16 s for their translations. This means that about 9.6 MsbA proteins and
20 LpxK proteins are translated over the lifetimes of their respective mRNAs. Thus, LpxK is
likely to be synthesized about 2.1 times faster than MsbA. Both LpxK and MsbA are membrane
proteins, so we assumed that they had similar degradation rates [69]. This meant that the syn-
thesis rate ratio also represented the protein concentration ratio. MsbA has an abundance of
about 206 molecules per E. coli cell [62], from which we calculated that the LpxK abundance is
about 432 molecules.
Enzyme kinetics. We modeled all pathway reactions using single-substrate or bi-substrate
Michaelis-Menten mechanisms. We ignored reaction reversibility in most cases. This can lead
to misleading results in metabolic models because it ignores feedback effects that arise from
product inhibition and hence can prevent models from attaining a steady-state [70],[71]. How-
ever, it was legitimate here because our model includes regulatory feedbacks that extend over
most of the pathway length. These are alternative ways to enable models attain steady-state,
and in fact are typically more effective than reversible reactions [72]. Also, most of the lipid A
reactions are likely to be nearly irreversible, due to either favourable energetics or much more
abundant substrates than products (e.g. the phosphorylation reaction catalyzed by LpxK is ef-
fectively irreversible because ATP is abundant in cells whereas ADP is not).
We used single-substrate Michaelis-Menten kinetics for the LpxC, LpxK, LpxL, LpxM, and
MsbA steps. Here, the metabolite flux is
d½P
dt
¼  d½S
dt
¼ kcat½E½S
Km þ ½S
ð1Þ
where [S] is the substrate concentration, [P] is the product concentration, [E] is the total en-
zyme concentration, kcat is the enzyme catalytic rate constant, and Km is the Michaelis con-
stant. Most of these kcat and Km values have been published using data from in vitro
experiments (Table 1), although we needed to estimate a few of them. (i) The speciﬁc activity
of LpxK in crude E. colimembrane extract was estimated to be 22 nmol/min/mg in a plasmid-
containing strain but 7-fold lower in wild type [65]. There are about 432 LpxK molecules per
cell and E. colimembranes include about 580,000 individual proteins [64], so the LpxK
purity in crude membrane is about 0.074%. Thus, the pure wild-type speciﬁc activity is about
4 μmol/min/mg, from which kcat is about 2.1 s
-1. We estimated that the LpxK Km value is
40 μM from a ﬁgure presented by Ray and Raetz [35]. Although Km estimations from crude
samples are prone to inaccuracies when the substrate can be catalyzed by other enzymes in the
lysates, there is no evidence of such competition for the LpxK substrate. (ii) We estimated the
LpxM catalytic rate constant, kcat, as 0.6 s
-1 from the speciﬁc activity of the enzyme in crude ly-
sates [42], much as we did for LpxK. We estimated the LpxM Km value from data shown in
Fig 6 of Clementz et al. [43]. To do so, we simulated Clementz et al.’s experiment using
COPASI [15], with the same enzyme and substrate concentrations that they used (0.1 μg/mL
and 25 μM for protein and KDO2-lipid IVA respectively in a 20 μL reaction mixture), from
AModel for Lipid A Biosynthesis in E. coli
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which we identiﬁed the Km value that corresponded to their ﬁgure results at a time of
30 minutes. (iii) We treated the MsbA catalyzed translocation of KDO2-lipid A across the
inner membrane as another Michaelis-Menten process, setting its Km value to 0.021 mM and
its kcat value to 166 s
-1, based on data shown in Fig 6 of [73].
We used single-substrate Michaelis-Menten kinetics with inhibition for the LpxH enzyme.
In this case, the metabolite flux is
d½P
dt
¼  d½S
dt
¼ kcat½E½S
ðKm þ ½SÞ 1þ ½PKi
  ð2Þ
where Ki is the inhibition constant and the other parameters are the same as in Eq 1. Assays
conducted on LpxH puriﬁed to 60% homogeneity displayed a speciﬁc activity of 63.2 μmol/
min/mg [33]. This implies that the pure enzyme speciﬁc activity is about 105 μmol/min/mg,
which is combined with the LpxH molecular weight of 26.8 kDa [33], to yield its kcat as about
47 s-1. The estimation of our Ki value is discussed below.
We used bi-substrate Michaelis-Menten kinetics for the forward LpxA, reverse LpxA, LpxB,
and WaaA catalysis of KDO2-lipid A steps. Treating the forward and reverse LpxA reactions as
independent irreversible reactions is legitimate in non-spatial models, such as ours, because
doing so does not introduce any new approximations (although, this is not true for spatial
models [74]). Most bi-substrate enzymatic reactions follow either a sequential or ping-pong
mechanism [75]. In the sequential mechanism, the enzyme forms a ternary complex with both
substrates before catalyzing the reaction. In the ping-pong mechanism, the enzyme binds one
substrate, forms one product, and then binds the second substrate and forms the second prod-
uct. The only bi-substrate reactions in the lipid A pathway that have been investigated in suffi-
cient detail to determine mechanisms are the steps catalyzed by LpxA [76] and LpxD [32],
both of which were found to follow the sequential mechanism. Lacking further experimental
evidence, we assumed sequential mechanisms for the other bi-substrate reactions in the lipid A
pathway as well. The sequential mechanism metabolite flux is
d½P
dt
¼  d½S1
dt
¼  d½S2
dt
¼ kcat½E½S1½S2ðKm1 þ ½S1ÞðKm2 þ ½S2Þ
ð3Þ
where [S1] and [S2] are the two substrate concentrations, with respective Michaelis-Menten
constants Km1 and Km2. We needed to estimate these parameters in some cases. (i) The LpxA
kinetic parameters were determined previously for the forward reaction [27], [76], but not for
the reverse reaction. Thus, we assumed the same Km values for the reverse reaction as for the
forward reaction (we set Km of ACP to that for β-hydroxymyristoyl-ACP, and Km of UDP-
3-O-[β-hydroxymyristoyl]-NAc to that for UDP-GlcNAc), based upon the likelihood that the
enzyme binding afﬁnities are not substantially affected by the acyl group transfer. However, we
set the reverse reaction kcat value to 100 times that of the forward reaction to account for the re-
action’s unfavourable equilibrium constant of approximately 0.01 [27]. (ii) We estimated the
LpxB kcat value by starting from the speciﬁc activity of LpxB puriﬁed to near homogeneity [63],
much as we did for LpxH, which resulted in a kcat value of 129 s
-1. (iii) The WaaA speciﬁcity
for KDO2-lipid A is 8.7 fold lower than for lipid IVA [40]. To account for this, we reduced the
kcat value for the former reaction by 8.7 fold while keeping other reaction constants the same.
Finally, we used bi-substrate Michaelis-Menten kinetics with inhibition for the LpxD and
WaaA steps. Assuming the sequential mechanism again, which was shown to be the correct
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mechanism for LpxD, the metabolite flux is
d½P
dt
¼  d½S1
dt
¼  d½S2
dt
¼ kcat½E½S1½S2
ðKm1 þ ½S1ÞðKm2 þ ½S2Þ 1þ ½PKi
  ð4Þ
We computed the WaaA kcat value as 16.7 s
-1 from the speciﬁc activity of the puriﬁed pro-
tein [14]. We computed the inhibition constant from results by Belunis and Raetz [40] which
showed that 100 μM of lipid A inhibited the WaaA reaction by 24.1% in vitro. Their experi-
mental conditions involved puriﬁed enzyme and substrates, thus excluding the possibility of
FtsH playing a role in the inhibition. Whilst assuming a non-competitive inhibition (Eq 4), in
which case Km is constant, we derived that at 100 μM of inhibitor and excess CMP-KDO, a
24.1% reduction in the reaction rate implies that Ki is about 0.0317 mM.
LpxC andWaaA synthesis and degradation. We included translation and degradation
reactions for LpxC and WaaA in our model so that we could explore the effects of their regula-
tion via FtsH proteolysis. As in the rest of the model, we accounted for degradative protein
turnover within cells, but not protein loss through sequestration into daughter cells or the
translation that is required to replace those proteins.
We modeled LpxC andWaaA synthesis with zeroth order reaction kinetics, in which the
production rate is constant. This approach combines transcription, translation, and any trans-
location into a single reaction step. We modeled the degradation of these proteins with a first
order reaction for degradation that is not catalyzed by FtsH, and also an independent reaction
obeying mass action kinetics for degradation that is catalyzed by FtsH (Michaelis-Menten ki-
netics might be more appropriate, but those parameters cannot be computed from available
data). Together, these processes combine to give the net production rate for each of these pro-
teins as
d½P
dt
¼ ktranslate  kdegrade½P  kFtsH ½FtsH½P ð5Þ
where [P] is the concentration of the LpxC or WaaA protein, ktranslate is the production rate
constant, kdegrade is the rate constant for uncatalyzed degradation, and kFtsH is the rate constant
for FtsH degradation.
To determine the production and degradation parameters for LpxC, we started with results
presented in Schäkermann et al [14] which showed that LpxC in wild-type E. coli can have a
half-life of 120 minutes under nutrient and temperature conditions that lead to rapid growth.
We assumed that the long LpxC half-life arose because FtsH was essentially inactive under
these conditions. This implies that the uncatalyzed LpxC degradation has a half-life of about
120 minutes and kdegrade is about 9.62×10
–5 s-1. Separately, it has been shown that cells with in-
hibited FtsH activity, using a temperature sensitive mutant, exhibit 4-fold elevated LpxC con-
centrations [47], thus increasing LpxC counts from about 385 molecules to about 1540
molecules. Combining this molecule count with the kdegrade value and the assumption that
[FtsHLpxC] equaled zero in this mutant, enables Eq 5 to be solved for steady-state conditions
to give a ktranslate value of about 0.148 molec./s. Next, combining the kdegrade, ktranslate, and the
wild-type LpxC count of 385 molecules enables Eq 5 to solved for steady-state to give that
kFtsH[FtsHLpxC] is 2.89×10
–4 s-1. We cannot solve for kFtsH by itself from the available informa-
tion, but estimate its value below.
We computed the WaaA synthesis and degradation parameters similarly. First, a mutant
without FtsH maintained about 72% of its WaaA concentration after 30 minutes [50], from
which we computed that kdegrade is about 1.8×10
–4 s-1. Next, the half-life of WaaA in wild-type
cells under optimal growth conditions is about 10 minutes [50]. This gives the combined
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degradation rate constant, kdegrade + kFtsH[FtsHWaaA], as approximately 1.15×10
–3 s-1, imply-
ing that the catalyzed degradation rate constant is about 9.8×10–4 s-1. Combining the total deg-
radation rate with the wild-type WaaA abundance of 153 molecules per cell gives the protein
translation rate, ktranslate, as 0.176 molecules/s.
FtsH activation and inactivation. Our model treats FtsH activation in a substrate-specific
manner, but with the constraint that the total FtsH count per cell is conserved at 579 molecules
[62]. We did not account for FtsH sequestration through activation for other degradation tar-
gets, such as RpoH or misfolded proteins. We modeled FtsH activation and inactivation with
mass action kinetics, meaning that we treated net FtsH activation towards a specific substrate
according to
d½FtsH
dt
¼ kactive½activator½FtsH  kinactive½FtsH ð6Þ
where [FtsH] represents the concentration of a substrate-speciﬁc active form of FtsH, [activa-
tor] represents the concentration of the substrate-speciﬁc activator (lipid A disaccharide for
the LpxC substrate and KDO2-lipid A for the WaaA substrate), and [FtsH] represents the con-
centration of inactive FtsH. The ﬁrst term on the right hand side represents the activation rate
and the second represents the inactivation rate.
The FtsH proteolysis rate, for either LpxC or WaaA, depends on three parameters, kactive,
kinactive, and kFtsH. However, the available experimental data only enabled us to quantify the
product kFtsH[FtsH], for each substrate, with values given above. Thus, the system is underde-
termined, with multiple possible combinations of parameters values that are each equally good
at agreeing with the available data. We addressed this by making a few assumptions. First, we
assumed that during growth on rich media, 10% of the total FtsH is activated for degradation
of LpxC, 10% is activated for degradation of WaaA, and 80% is inactive (i.e. there are 58 copies
of FtsHLpxC, 58 copies of FtsHWaaA, and 463 copies of inactive FtsH). This is intuitively sensi-
ble because it assumes a reasonably large reservoir of inactive FtsH to allow for strong regulato-
ry control and other proteolysis tasks. Combining this assumption with the prior values for the
kFtsH[FtsH] products yield kFtsH of 2.0 mM
-1s-1 for LpxC and kFtsH of 6.8 mM
-1s-1 for WaaA.
Secondly, we assumed that both kinactive values equal 0.1 s
-1. This gives the active states a 10 s
lifetime, which is fast enough to enable rapid control. We then solved for kactive from the
steady-state version of Eq 6, while substituting in this inactivation rate constant, the assumed
FtsH and FtsH concentrations, and the activator concentrations that arose from simulations
in which we fixed the LpxC andWaaA enzyme counts to the values listed in Table 1 (activator
counts were 35,600 and 155 molecules, respectively). Results are that kactive is 0.14 mM
-1s-1 for
LpxC and 32.3 mM-1s-1 for WaaA. Note that the assumptions made here do not affect the mod-
el’s steady-state condition at all, making them necessary for running simulations but irrelevant
to the results that we present below.
Results
Model adjustment
Our initial model, defined using literature parameter values where available and our best esti-
mates elsewhere, exhibited a lipid A production rate that was much too low. Also, several inter-
nal metabolite concentrations accumulated to very high levels. We addressed these problems
with two model adjustments.
LpxM enzyme count. Our initial model simulations only produced about 20% of the
1 million lipid A molecules that E. coli cells actually produce per generation. This did not
change even if we removed FtsH degradation of LpxC andWaaA and all negative feedbacks.
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We found that this slow production rate arose from LpxM acting as a bottleneck in the path-
way, as seen by its substrate increasing linearly over time, rather than stabilizing at a steady-
state level. This may indicate that cells have more than the 186 LpxM proteins that proteomic
research on the cell cytoplasm indicated [62], which would not be surprising because LpxM is
an integral membrane protein. Alternatively, it may be that other enzymes acylate LpxM’s sub-
strate in parallel to LpxM; in particular, LpxL and LpxP can catalyze essentially the same lipid
A synthesis reaction [43], [45]. Assuming the former explanation, we increased the LpxM mol-
ecule count 20 fold, from 186 to 3720. This removed substrate accumulation upstream of
LpxM and caused the model to produce lipid A at about 1 million molecules per generation.
LpxH product inhibition. Our initial simulations also resulted in high lipid X concentra-
tions, which rose over the course of several cell generations and stabilized at about 400,000 cop-
ies. In contrast, 2000 copies were observed in vivo [77]. We found that the accumulation arose
because LpxH rapidly diverted UDP-2,3-bis(β-hydroxymyristoyl)-D-glucosamine towards
lipid X, while LpxB only consumed lipid X in a 1:1 ratio with UDP-2,3-bis(β-hydroxymyris-
toyl)-D-glucosamine. For this reason, we assumed that LpxH is regulated through product in-
hibition, as described above. The experimental lipid X count was reproduced when we set Ki to
0.2 μM; however, this value is unusually small and it created a bottleneck in the pathway,
which we observed as accumulation of the LpxC product and decreased lipid A production
(negative feedback at LpxD prevents accumulation of its product, backing the accumulation up
to the LpxC product instead). Thus, we decided to decrease LpxH inhibition by increasing Ki.
As mentioned above, mutants with inactive FtsH exhibit 4-fold increased LpxC concentrations
[47]; they were also shown to produce 32% more lipid A (Table 1 of [47], comparing their
AR3317 at 30°C vs. 42°C, or their AR3289 vs. AR3291). We decided to set the LpxH inhibition
constant so that our model would reproduce this result, which turned out to be a Ki value of
0.015 mM. This value was large enough that it did not cause the LpxC product to accumulate
in wild-type cells. However, the LpxC product still accumulated in cells without FtsH due to
the higher metabolite flux through the LpxC step and the lack of product inhibition at this step.
This Ki value caused the steady-state lipid X concentration to be about 22,000 molecules, in ei-
ther wild-type or FtsH mutant cells, which is much larger than the 2000 that were observed ex-
perimentally [77]. We found that this difference cannot be eliminated simply by adjusting
enzyme kinetic parameters without creating large metabolite accumulations, which suggests
that this region of the biosynthesis pathway includes dynamics that are not in our model. For
example, the difference could arise from metabolic channeling between the LpxH and LpxB
enzymes.
Comparison of model with experiment
Mutant with defective LpxA. Anderson et al. [27] showed that cells that have defective
LpxA copies, which have at least 150-fold lower LpxA specific activities, have 5- to 10-fold in-
creased LpxC concentrations and an LPS content that is reduced by approximately 30% (their
strain SM101 at 30°C). We modeled this perturbation by decreasing the LpxA kcat value by
150 fold, to 0.048 s-1. Our simulation resulted in a 3.9 fold increase in LpxC levels, in reason-
ably close agreement with experiment. This is essentially the maximum LpxC increase that our
model can produce under any condition, arising from our assumption that cells with complete-
ly inactive FtsH exhibit 4-fold higher LpxC concentrations [47]. However, our model only pro-
duced 24,000 lipid A molecules per generation, rather than the 1.1 million molecules that it
produces with our standard parameters (Table 1), which is a reduction of 98%. Our results
were unaffected by whether we decreased the LpxA reverse reaction kcat value or not, or even if
the reverse reaction was removed altogether. This limitation is clarified by noting that the
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reaction velocity of the LpxA step is simply kcat[LpxA] in these conditions, from Eq 1, which
works out to 57,000 product molecules per generation; these need to dimerize to form lipid A,
meaning that the LpxA step limits lipid A production to only 29,000 molecules per generation,
in close agreement with our model result. Thus, Anderson et al.’s [27] observation that LpxA
in the SM101 strain exhibits a 150-fold reduced kcat value but reduces the lipid A production
rate by only 30%, is not compatible with our model. This is because their results cannot arise
from our assumed LpxA protein count or kcat parameters. The disagreement implies that these
parameters are incorrect by more than an order of magnitude, which seems unlikely, or poten-
tially, there is an alternate biosynthetic pathway; for example, perhaps LpxD can catalyze what
is normally the LpxA step.
Inhibition of LpxC. CHIR-090 is a powerful antibiotic that controls E. coli and Pseudomo-
nas aeruginosa growth with efficacy that is similar to the popular drug ciprofloxacin [30]. Its
minimum inhibitory concentration (MIC) on E. coli, meaning the lowest drug concentration
required to inhibit visible growth, is between 0.20 and 0.25 μg/ml [9], [20]. Barb et al. showed
that CHIR-090 acts by inhibiting LpxC through the two-step mechanism [9]
LpxCþ IÐ
k3
k4
LpxC IÐ
k5
k6
LpxC I  ð7Þ
where LpxC-I represents a complex between LpxC and the CHIR-090 inhibitor, and I repre-
sents an enzyme/inhibitor isomer [9]. They reported the reaction kinetics parameters as k4/
k3 = 4 nM, k5 = 1.9 min
-1, and k6 = 0.18 min
-1 [9]. They did not report separate parameters for
k3 and k4, but their results only becomes logical if this complexation reaction comes to equilib-
rium reasonably quickly. Thus, we assume here that k4 = 0.1 s
-1, from which we compute that
k3 = 25000 mM
-1s-1. We added this mechanism to our model to see if it would exhibit the same
inhibitory effect. Firstly, we noticed that ﬁxing the free inhibitor concentration to a constant
value does not affect the steady-state biosynthesis pathway at all. This seems reasonable be-
cause the LpxC count is not ﬁxed in our model, but arises from the LpxC translation and degra-
dation rates, which the inhibitor does not affect (the reversibility of inhibitor binding implies
that, at steady-state, LpxC is sequestered into and released from complexes at the same rate).
On the other hand, the inhibitor induces a very strong transient effect. Fig 4A shows the
amount of lipid A produced by the model over the course of 30 minutes, in which all metabo-
lite concentrations started at steady-state and then CHIR-090 was added at time 0. We as-
sumed that the CHIR-090 MIC corresponds to the inhibitor concentration that reduces lipid A
production by 50%, based on results that show that this is when cells become non-viable [11].
From the data shown in Fig 4A, our model cells became non-viable when the free intracellular
CHIR-090 concentration exceeds 0.31 molecules/cell, which is 0.76 nM. Clearly, molecule
counts are discrete, implying that these are time-averaged quantities. This MIC corresponds
closely with the in vitro inhibition constant of CHIR-090, Ki, which is 0.5 nM [9]. Taking the
in vivoMIC as 0.25 μg/ml, and using the CHIR-090 molecular weight of 437.4 g/mol, shows
that the MIC is 570 nM of extracellular CHIR-090. Combining this with the intracellular MIC
suggests that the intracellular CHIR-090 concentration is about 1000 fold lower than the extra-
cellular concentration.
Correlation between LpxC half-life and cell generation time. Schäkermann et al. [14]
showed that faster growing cells, such as those grown in rich media and/or at higher tempera-
tures, stabilize LpxC more rapidly than slowly growing cells. We simulated these experiments
as a way of validating our model. We only considered Schäkermann et al.’s results for rich me-
dium because all of our model parameters were estimated from experiments performed with
rich medium. For each LpxC half-life value from Table 2 of Schäkermann et al. [14], we used
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Eq 6 to compute the concentration of FtsHLpxC that would produce it (here, ktranslate was 0,
and kdegrade and kFtsH were the values from Table 1). Next, we changed our standard model in
two ways: we adjusted the LpxC kcat value to account for the given growth temperature accord-
ing to data shown in Fig 2 of Jackman et al. [10], and we adjusted the rate of FtsH activation
for LpxC degradation, kactive, until the model exhibited the desired FtsHLpxC concentration.
The rationale for the latter change is that cells might regulate LpxC half-lives by altering the
FtsH activation rate. Finally, we computed the cell generation time from the steady-state lipid
A production rate in this adjusted model, under the assumption that a generation time is deter-
mined by how long a cell requires to produce 1 million lipid A molecules. Fig 4B shows that the
model results agree reasonably well with the experimental results, which supports our model.
We suspect that our model underestimates cell generation times with long LpxC half-lives be-
cause it does not account for other cell processes, which may limit cell division rates at these
fast growth rates.
Overexpression of LpxC. Führer et al. [48],[49] cloned the lpxC gene into an inducible ex-
pression vector and then induced with 0.01% or 0.1% arabinose, which overexpressed the
LpxC enzyme. They did not quantify the extent of overexpression, but comparable cells in-
creased protein expression by 100 to 200 fold with 0.01% arabinose induction [78]. Führer
et al. found that LpxC overexpression increased LPS amounts in cells, by about 1.27 fold and
1.7 fold in cells induced with 0.01% and 0.1% arabinose respectively (our estimates from Fig 4
of [49]). They also found that overexpressing LpxC with 0.01% arabinose resulted in a protein
half-life of about 11 minutes [48].
We simulated arabinose induction by increasing our model’s LpxC translation rate constant
and observing its effect on the lipid A production rate and LpxC half-life (Fig 4C). As in the ex-
periment, overexpressing LpxC led to increased lipid A production and shorter LpxC half-
lives. However, these effects stopped changing once LpxC was overexpressed about 4-fold, in
contrast to the 100 to 200 fold overexpression that the experiments may have produced. At
higher than 4-fold overexpression, the LpxC product accumulated in our model because LpxD
became a bottleneck; this prevented further changes to the LpxC lifetime and lipid A produc-
tion rate. Nevertheless, if one assumes a more modest experimental overexpression, then our
results agree well with the 0.01% arabinose induction experiment. In particular, at 2.8 fold
overexpression, our model shows a 1.27 fold increase of lipid A production and a 14 minute
LpxC lifetime, which is reasonably close to the 11 minutes that Führer et al. observed [48]. The
0.1% arabinose induction experiment is harder to match because this resulted in 1.7 fold more
LPS, whereas LpxC overexpression could not produce more than 1.36 fold more lipid A in our
model due to LpxD acting as a bottleneck. A possible explanation for this difference is that
Führer et al. found that LpxC overexpression led to longer cell generation times [48], in addi-
tion to the effects mentioned above. Thus, it may be that cells produce lipid A only 36% faster
than normal, but they take twice as long to divide, leading to 1.7 fold more LPS in cells. Togeth-
er, these results show that our model agrees qualitatively with Führer et al.’s LpxC overexpres-
sion experiments, and it could agree quantitatively as well, but this cannot be assessed
currently with the available experimental data.
Substrate limitation. It is well known that organisms grow more slowly when nutrients
are limited. For example, Taniguchi et al. [79] observed that E. coli grown on minimal medium
had a 150 minute generation time. Replicating this in our model was straightforward. As
above, we used the assumption that a cell generation is the time that the model takes to produce
1 million lipid A molecules. Our model reproduces the 150 minute generation time when any
one substrate limits the lipid A production rate, with 16,000 UDP-GlcNAc molecules, or 43 β-
hydroxymyristoyl-ACP molecules, or 510 CMP-KDO molecules. It also reproduces the 150
minute generation time when all three substrates are partially limiting, with 80,000
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UDP-GlcNAc, 210 β-hydroxymyristoyl-ACP, and 2400 CMP-KDOmolecules (about 5 times
the prior numbers). Thus, substrate limitation does increase generation times in the model,
as expected.
Fig 4. Comparison of model with experiment. (A) Effect of CHIR-090 antibiotic on lipid A production. Themodel (Fig 2 plus Eq 7) was started with all
metabolites at their steady-state concentrations without CHIR-090. Then, antibiotic was added and the total amount of lipid A produced over the following 30minutes
was quantified, shown with the solid black line. The free antibiotic concentration, quantified as the average number of uncomplexed CHIR-090molecules/cell, was
kept constant. The black dashed line shows our estimate of the MIC for the intracellular antibiotic concentration and the red dashed line shows the antibiotic inhibition
constant [9]. (B) Correlation between LpxC half-life and cell generation time. The experimental data (red circles) are from Schäkermann et al. [14], who varied
generation times using different growth conditions and then quantified LpxC half-lives. Themodel data (black diamonds) were collected by varying the LpxC half-
lives (and LpxC kcat) and then quantifying the generation times, defined here as the time required to produce 1million lipid Amolecules. Lines are least-difference
best-fits to the data using the function y = c1/x + c2, primarily to guide the eye. (C) Effect of overexpressing LpxC on the LpxC half-life (black curve, left axis) and on
the lipid A production rate, measured relative to the wild-type production rate (blue curve, right axis). The dashed line shows the wild-type condition using the LpxC
translation rate from Table 1.
doi:10.1371/journal.pone.0121216.g004
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However, these results disagree with those of Schäkermann et al. [14] in that the low sub-
strate concentrations in the model led to decreased lipid A disaccharide counts, which caused
slower LpxC degradation, whereas Schäkermann et al. showed that substrate limitation leads to
faster LpxC degradation. They found that growth in minimal medium leads to an LpxC half-
life of about 10 minutes [14]. This appears to occur because substrate limiting conditions lead
to increased (p)ppGpp alarmone concentrations, which increase FtsH expression [80]. Our
model could agree with these data as well, but only if the total FtsH count was increased
roughly 25-fold, to about 14,000 molecules (we also used 250,000 UDP-GlcNAc, 650 β-hydro-
xymyristoyl-ACP, and 7600 CMP-KDOmolecules, which are about 15 times higher than the
single-substrate limitation values presented above). This modified model exhibited a 10 minute
LpxC half-life and a 160 minute generation time, in close agreement with results presented in
Schäkermann et al. The cost of achieving this agreement was that the high FtsH concentration
led to fast WaaA degradation, which made WaaA catalysis of CMP-KDO the rate-limiting step
as observed by the fact that lipid IVA accumulated rapidly. The large FtsH expression increase
and the lipid IVA accumulation suggest that our model is incorrect for substrate limiting condi-
tions. In particular, achieving the combination of rapid LpxC degradation and relatively low
lipid A disaccharide concentrations, without increasing the FtsH concentration 25-fold, re-
quires additional LpxC degradation regulation.
Overexpression of LpxK stabilizes LpxC. As mentioned above, a preliminary model that
did not include FtsH feedback regulation exhibited lipid A disaccharide accumulation (Fig 3),
which led us to propose that this metabolite is the feedback source for LpxC degradation. If
this is the case, then it follows that LpxK overexpression should reduce lipid A disaccharide
concentration, which would down-regulate LpxC degradation and lead to higher LpxC concen-
trations. We tested this hypothesis experimentally. Fig 5A shows that this is indeed the case.
LpxC concentrations increased substantially with LpxK overexpression, even under modest
IPTG induction. We tested the same perturbation in our model, finding exactly the same re-
sults (Fig 5B). These results are consistent with the assignment of lipid A disaccharide as the
feedback source. In contrast, the opposite correlation between LpxC concentration and LpxK
overexpression would be expected if the feedback source were downstream of LpxK, so our ex-
periments provide strong evidence against that possibility. Similarly, only a very weak correla-
tion would be expected if the feedback source were further upstream of LpxK, meaning at
or before the lipid X metabolite, due to the near irreversibility of the LpxB enzyme, so our ex-
periments provide strong evidence against those possibilities as well. Thus, our experiments
strongly indicate that lipid A disaccharide is the feedback source for activating FtsH for LpxC
degradation.
Model predictions
Lipid A synthesis sensitivity on enzyme concentration. We investigated the sensitivity of
lipid A synthesis on enzyme counts in several ways. First, we investigated the effect of small en-
zyme concentration variations. Using the methods of metabolic control analysis [70], [81], we
defined flux control coefficients as
Ci ¼
@ln J
@lnEi
 100% ð8Þ
where i represents one of the 10 pathway enzymes, J represents the biosynthesis rate of lipid A
at the outer membrane, and Ei represents the count of enzyme i. We quantiﬁed ﬂux control co-
efﬁcients by starting the model at steady-state, varying an enzyme count by 5%, and observing
the effect on the lipid A production rate. When we set the three pathway substrates to
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saturating concentrations and used the “open-loop” case, in which we removed negative feed-
back through FtsH but kept the wild-type enzyme counts from Table 1, the pathway ﬂux was
solely controlled by LpxC (Fig 6A black bars). This is consistent with the view that LpxC is the
rate-limiting step of lipid A synthesis [48],[55]. However, the “closed-loop” case, in which we
replaced the feedbacks through FtsH and thus returned to a better model for the wild-type
pathway, showed no sensitivity to LpxC concentration perturbations (Fig 6A red bars). Instead,
the feedback caused the LpxC enzyme count to return to its steady-state level, which meant
that the perturbation did not affect the lipid A production rate. LpxK was the sole enzyme that
controlled pathway ﬂux in the closed-loop case.
Yet different enzymes controlled pathway flux when we reduced substrate concentrations.
For each substrate, we set its concentration to the value that led to about 0.5 million lipid A
molecules produced per generation and then computed flux control coefficients for each en-
zyme. Limiting UDP-GlcNAc shifted control to LpxA. This contrasts the view that LpxA does
not affect pathway flux, simply because it is reversible and has an unfavorable equilibrium con-
stant [27]. Limiting β-hydroxymyristoyl-ACP shifted control to LpxD, LpxH, and LpxB (60%,
Fig 5. Overexpression of LpxK increases LpxC concentration. (A) Lower row shows LpxK bands on an
SDS-PAGE gel, arising from overexpression induced with the amount of IPTG shown at the top of each
column. The upper row shows the resultant LpxC bands on aWestern blot for the same induction levels. (B)
Model prediction of LpxC overexpression arising from LpxK overexpression. The model was that shown in
Fig 2 but with different LpxK enzyme counts, at steady-state.
doi:10.1371/journal.pone.0121216.g005
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20%, and 20%, respectively). Finally, limiting KDO-CMP shifted control to WaaA in the open-
loop case, and to MsbA in the closed-loop case. These results show that control of pathway flux
is typically localized to relatively few enzymes, but ones which depend on the substrate
concentrations.
Fig 6. Sensitivity of lipid A production rate on enzyme abundance. (A) Black bars show enzyme control
coefficients for the open-loop case, in which wild-type enzyme counts were assumed but FtsH regulation was
disabled. Red bars show enzyme control coefficients for the closed-loop case, in which FtsH regulation was
enabled. (B) Enzyme abundance reductions that led the model to produce 0.5 million lipid A molecules per
cell generation for the open-loop (black bars) and closed-loop (red bars) cases.
doi:10.1371/journal.pone.0121216.g006
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Next, we investigated the sensitivity of lipid A biosynthesis on enzyme counts for the case of
large perturbations, assuming saturating substrate concentrations. For each enzyme, we deter-
mined what fraction of the wild-type count (Table 1) would lead to 0.5 million lipid A mole-
cules produced in 30 minutes. In the open-loop case, the production rate was most sensitive to
the LpxC and LpxK enzyme counts (Fig 6B black bars). In the closed-loop case, as before,
LpxC perturbations were ineffectual because its concentration was regulated through feedback.
As a result, the pathway was most sensitive to LpxK (Fig 6B red bars).
WaaA Regulation. Katz and Ron’s finding that the concentration of WaaA is regulated
through degradation by FtsH [50] leads to the obvious question of why it is regulated in addi-
tion to LpxC. From our sensitivity analysis, one answer may be that WaaA regulation is used to
control pathway flux when the CMP-KDO concentration is limiting (Fig 7A). In this situation,
the lipid A synthesis rate is insensitive to small changes in the LpxC concentration, making
that less useful for regulation, but is controlled by the WaaA concentration instead. Also, re-
ducing lipid A production when CMP-KDO is limiting would conserve KDO for other uses.
For example, KDO can be catalyzed by KDO aldolase to produce D-arabinose and pyruvate
[82]. Although it has been suggested that CMP-KDO synthesis is the rate-limiting step to lipid
A synthesis [83], the strong effects of LpxC and the other upstream enzymes, discussed above,
indicate that this is not the normal case. Additionally, our model shows that CMP-KDO limita-
tion leads to rapid lipid IVA accumulation, with no apparent correction mechanism. Together,
these results point to the likelihood that WaaA regulation helps control the lipid A production
rate when the CMP-KDO concentration is low, but probably not so low as to be rate-limiting.
A second possible explanation for WaaA’s regulation is that it might decrease reactions with
undesirable substrates [50], brought about by the fact that WaaA has a low substrate specificity.
As mentioned previously above, WaaA can glycosylate a wide range of lipid acceptors, includ-
ing KDO2-lipid A in particular [39], [40], which we included in our model architecture as pro-
duction of alternate lipid A. We ran simulations with different rate constants for WaaA
degradation by FtsH. We found that slower WaaA degradation led to higher steady-state en-
zyme counts, which then led to higher relative amounts of alternate lipid A (Fig 7B). Thus, our
model agrees with suggestions that WaaA regulation might help regulate the lipid A molecule
composition [50]. This mechanism functions even if CMP-KDO is in excess.
Discussion
We constructed a model of the E. coli lipid A biosynthesis pathway, including its regulation,
using parameters derived from published experimental data. After increasing the LpxM copy
number and adding product inhibition to LpxH, this model agreed well with the observed lipid
A production rate and exhibited steady-state metabolite concentrations. This model also
agreed qualitatively with all of the experiments that we investigated, including ones in which
LpxA was defective, LpxC was inhibited with an antibiotic, LpxC lifetimes were compared with
cell generation times, LpxC was overexpressed, and substrate concentrations were limited. The
model also agreed well with experiments in which we overexpressed LpxK. We are not aware
of any published experiments that our model would be expected to disagree with. From this
model, we found that the lipid A biosynthesis rate is controlled by LpxC, but only if substrates
are in excess and if feedback regulation is ignored. However, LpxK becomes the controlling en-
zyme if feedback regulation is included, as it is in living cells, and other enzymes gain control if
substrate concentrations are below saturation levels. We also found that WaaA may be regulat-
ed in order to control the lipid A production rate when the CMP-KDO concentration is limit-
ing, and/or to control the ratio of normal to alternate lipid A that is produced.
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Fig 7. WaaA regulation. (A) The flux control coefficient of WaaA as a function of the CMP-KDO substrate
concentration. This is for the open-loop case, in which wild-type enzyme counts were assumed but FtsH
regulation was disabled. (B) The ratio of alternate lipid A to normal lipid A (KDO2-lipid A) as a function of the
number of WaaA proteins. All parameters are the same as in Table 1, except that theWaaA proteolysis rate
constant was changed in order to alter theWaaA degradation rate and hence theWaaA steady-state copy
number. The maximum enzyme count shown arose from no FtsH mediated proteolysis. The dashed line
indicates the wild-type count, from Table 1.
doi:10.1371/journal.pone.0121216.g007
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Quantitative disagreements between our model and experiments are particularly useful be-
cause they show which model assumptions are likely to be incorrect. These errors then enable
new insights about the true system behaviour. In particular: (i) Our initial model produced
lipid A at 20% of the observed rate and exhibited LpxM substrate accumulation, which suggest
that LpxM is actually present at a much higher concentration than was measured with proteo-
mic methods [62]. (ii) High modeled levels of lipid X suggest that the LpxH kinetics are regu-
lated by product inhibition, and also that LpxH and LpxB may form a complex that performs
metabolic channeling. (iii) The model exhibited 4-fold increased LpxC when LpxA was made
defective, instead of the observed 5–10 increase [27]; this may arise from experimental differ-
ences, or due to unmodeled aspects of LpxC regulation, such as transcription regulation. (iv)
The model exhibited a 98% reduction in the lipid A synthesis rate when LpxA was defective, in-
stead of the 30% that was observed experimentally [27], which suggests the presence of alter-
nate metabolic routes around LpxA, such as by LpxD. (v) The model underestimated cell
generation times when LpxC had a very long half-live [14], which suggest that the growth rates
of fast growing cells are not limited by the lipid A production rate. (vi) The model could exhibit
the experimentally observed LpxC half-life and cell generation time when substrates were lim-
ited [14], but only when the total FtsH concentration was increased 25-fold; this suggests that
there are additional mechanisms that regulate LpxC degradation. None of these speculations
are proven by the model. Instead, they are possible solutions to situations in which the experi-
ments that we drew on to create the model do not agree with experiments that were used to test
the model. They provide hypotheses for further experimental investigation.
The combination of prior experimental results, our model, and our LpxK overexpression ex-
periments provide strong evidence for lipid A disaccharide being a primary feedback source for
LpxC degradation (Fig 5A). Furthermore, these same sources of information suggest that this
is the only feedback source among the chemical species that we modeled. However, there is
also evidence for other LpxC regulation mechanisms. As mentioned previously above, the
LpxC concentration also appears to be regulated by signals arising in the phospholipid synthet-
ic pathway [20],[24],[47]. Also, the substrate limitation studies mentioned above suggest the
presence of additional regulation mechanisms. Together, these point to substantial signal pro-
cessing taking place at FtsH, which then controls lipid A synthesis through LpxC.
Yet more pathway regulation may take place in other ways. For example, Ray and Raetz
[35] found that phospholipids, and especially cardiolipin, increase the catalytic activity of
LpxK. Based on our experiments, this increase would lead to higher LpxC concentrations and
hence faster lipid A production, which could help balance the phospholipid to LPS ratio. As an-
other example, overall protein production is slowed during substrate limiting conditions [84],
which undoubtedly reduces the concentrations of the lipid A synthesis enzymes and hence re-
duces the lipid A synthesis rate. The significance of this effect was illustrated by Zeng et al.
[20], who found that strains that possess mutations in the thrS gene, whose function is vital to
overall protein synthesis, were resistant to LpxC inhibition.
There are several possible purposes for WaaA regulation. First, it may serve to regulate lipid
A production, which our model showed is possible, but only if CMP-KDO is at least partially
limiting. Also, it may serve to regulate the relative production of lipid A and alternate lipid A
[50], which our model also showed is possible. In support of the latter role, some of the precur-
sors for other substrates that can be glycosylated by WaaA could not be detected in wild-type
E. coli [77], suggesting that this step is tightly controlled. The situation changes at elevated tem-
peratures, where these alternate substrates accumulate [85] and, probably not coincidentally,
WaaA is degraded faster under these conditions [50]. Furthermore, it is well established that
the composition of lipids within bacterial membranes are altered as a response to temperature
fluctuations and growth rate changes [86], [87], [88], presumably to control membrane
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fluidity. Yet another proposed purpose for WaaA regulation is to balance the synthesis of the
sugar and lipid moieties of KDO2-lipid A [50]. However, this explanation seems unlikely be-
cause the uptake of these moieties by WaaA is always 2:1, independent of its regulation.
Our model can help elucidate which lipid A pathway enzymes are likely to be good or poor
antibacterial targets. Most of the best known inhibitors of the LPS pathway to date have been
directed at LpxC [11], [30], [89], including the CHIR-090 antibiotic discussed above, presum-
ably because most intracellular synthesis regulation takes place at LpxC. However, our sensitiv-
ity analysis showed that this intracellular regulation may actually make LpxC a poor drug
target because it enables the cell to counteract external perturbations. Indeed, it was recently re-
ported by Walsh and Wencewicz [90] that the development of CHIR-090 has been hampered
due to the ease of pathogen mutation to resistance. On the other hand, our model suggests that
LpxK would make a good target, as initially suggested by Emptage et al. [91]. LpxK is an essen-
tial enzyme without alternative synthetic routes, so strong inhibition would arrest lipid A pro-
duction. Also, LpxK does not appear to be regulated (except possibly by cardiolipin [35]),
which might make cells unable to counteract its inhibition. Additionally, when we accounted
for feedback regulation, we found that the lipid A production rate is particularly sensitive to
the LpxK concentration (Fig 6). And finally, inhibiting LpxK would lead to lipid A disaccharide
accumulation. Lipid A disaccharide is cytotoxic [65] and its accumulation would lead to LpxC
down-regulation, which would further repress lipid A production.
A central theme of cell biology modeling method development is that non-spatial, non-sto-
chastic models are too simplistic [92],[93]. In response, new software tools offer support for
stochastic reaction dynamics and spatial localization of proteins. In this case, we started this re-
search using the Smoldyn simulator [16], which accurately addresses stochasticity and spatial
detail, but found that simulations ran too slowly and the spatial detail did not affect the results.
Thus, we switched to StochKit [17], which performs stochastic simulations but ignores spatial
localization. Again, the stochastic detail proved unnecessary. We finally settled on non-spatial
deterministic simulations. These simple simulations were appropriate in this case because the
lipid A pathway is sufficiently poorly parameterized through experimental work. Therefore, in-
cluding additional detail would have only complicated the model further. However, more de-
tailed simulation methods will likely become useful as the lipid A synthesis becomes better
characterized. For example, we showed that time-averaged intracellular CHIR-090 antibiotic
count in cells was about 0.3 molecules, implying that it is present in extremely low copy num-
bers. This could lead to strong stochastic effects. Also, our results suggest the presence of inter-
esting dynamics between LpxH and LpxB, such as metabolic channeling. These might be best
modeled using spatial simulation methods.
In conclusion, we present a quantitative model of lipid A biosynthesis and its regulation.
The core biosynthesis pathway agrees with the commonly accepted architecture, while the reg-
ulation elements are largely new. Our model agrees qualitatively with a wide range of experi-
mental results, but also shows substantial quantitative differences. Thus, our model is not a
final picture of lipid A biosynthesis, but instead represents the best understanding of lipid A
synthesis available to date.
Supporting Information
S1 File. COPASI file of lipid A biosynthetic model in E. coli using parameters described in
Table 1.
(CPS)
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S2 File. COPASI file modelling the effect of CHIR-090 antibiotic on lipid A production.
Parameters are same as in S1 with the inclusion of Eq 7.
(CPS)
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